The decision ensures that the merger between Mylan and Upjohn does not harm competition

REACH2 is the first Phase III study in steroid-refractory acute graft-versus-host-disease (GvHD) to have met its primary endpoint

Laboratories and laboratory technology are perhaps the most important component of today’s medicine – they save and secure […]

Imagine a Fitbit that measures much more than steps, heart rate, and calories burned. It continually tracks all […]

Three Boston University computer scientists and engineers are working on a smartphone app that could let people know […]

Covid-19Care home residents and staff are promised testsThe pledge to boost covid-19 testing for staff in UK care […]

Updated Date: Wed, 15 Apr 2020 00:00:00 EDT

Updated Date: Wed, 15 Apr 2020 00:00:00 EDT

Updated Date: Wed, 15 Apr 2020 00:00:00 EDT

Updated Date: Wed, 15 Apr 2020 00:00:00 EDT